$26.95
11.20% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Instil Bio Inc Stock price

$26.95
+14.10 109.73% 1M
-0.63 2.28% 6M
+7.86 41.17% YTD
+15.91 144.11% 1Y
-93.05 77.54% 3Y
-373.05 93.26% 5Y
-373.05 93.26% 10Y
Nasdaq, Closing price Fri, May 30 2025
-3.40 11.20%
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Key metrics

Market capitalization $176.79m
Enterprise Value $157.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-50.85m
Free Cash Flow (TTM) Free Cash Flow $-45.50m
Cash position $103.65m
EPS (TTM) EPS $-11.94
P/E forward negative
Short interest 11.87%
Show more

Is Instil Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Instil Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Instil Bio Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Instil Bio Inc forecast:

Buy
75%
Hold
25%

Financial data from Instil Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
13% 13%
-
- Research and Development Expense 9.95 9.95
62% 62%
-
-48 -48
31% 31%
-
- Depreciation and Amortization 3.12 3.12
21% 21%
-
EBIT (Operating Income) EBIT -51 -51
30% 30%
-
Net Profit -78 -78
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Instil Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Instil Bio Inc Stock News

Neutral
GlobeNewsWire
2 days ago
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 4:20PM ET on Thursday, June 5, 2025. A live webcast will be available using this weblink: http...
Positive
Seeking Alpha
7 days ago
Key catalyst: Phase 2 data from China in first-line NSCLC expected in 2H 2025, with enrollment completion projected for Q3 2025. The global non-small cell lung cancer therapeutics market size is projected to reach $66.20 billion by 2033. The U.S. strategy differs, focusing on dose-optimization as a bridging study for a future global phase 3 registration trial.
Neutral
GlobeNewsWire
9 days ago
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center.
More Instil Bio Inc News

Company Profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Head office United States
CEO Bronson Crouch
Employees 49
Founded 2018
Website instilbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today